Expand all sections

Rovalpituzumab tesirine

Extended indication Small-cell lung cancer (SCLC), 3L.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Rovalpituzumab tesirine
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Small-cell lung cancer (SCLC), 3L.
Manufacturer Abbvie
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Particularity New medicine
Expected Registration 2020
Orphan drug Yes
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

Patient volume

60

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2015: 1192 kleincellig longcarcinoom stadium 4. Expertopinie: Ongeveer 5% 3L, 60 patiënten.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.